Insights

Strategic partnerships Dren Bio recently entered a strategic collaboration with Sanofi to develop therapies for autoimmune diseases, signaling open opportunities for co-development, licensing, or manufacturing partnerships with large pharma to scale their power protein technologies.

High growth potential With private funding totaling around $155 million and revenue in the low hundreds of millions, Dren Bio is positioned for accelerated R&D and clinical expansion, presenting a gateway for investment syndicates, strategic investors, and milestone-driven collaborations.

Clinical progression DR-0201 is advancing in phase 1 trials for B-cell non-Hodgkin lymphoma, indicating near-term needs for CROs, biomarker labs, and manufacturing scalability partners to support clinical development and potential future commercialization.

Immunology focus Dren Bio specializes in bispecific and targeted myeloid engagers for cancer and autoimmune indications, creating cross-sell opportunities with companies seeking immuno-oncology platforms, cell therapy suppliers, or adjuvant technologies.

Market credibility Awards and major deals in 2024–2025, including collaborations with Novartis and recognition from Prix Galien USA, enhance credibility for sales discussions with tier-one biopharma and contract manufacturers seeking proven innovative partners.

Dren Bio Tech Stack

Dren Bio uses 8 technology products and services including CookieYes, Microsoft Excel, Microsoft 365, and more. Explore Dren Bio's tech stack below.

CookieYes

Cookie Compliance

Microsoft Excel

Editors

Microsoft 365

Veeva Systems

IT Infrastructure & Operations Management

Microsoft Office

Office Suites

Smartsheet

Project Management

Box

Team Collaboration

Adobe Creative Suite

Visualisation Software

Dren Bio Email Formats	Example	Percentage
FLast@drenbio.com	JDoe@drenbio.com	98%
LF@drenbio.com	DJ@drenbio.com	1%
FL@drenbio.com	JD@drenbio.com	1%

Dren Bio Email Formats

Example

Percentage

FLast@drenbio.com

JDoe@drenbio.com

98%

LF@drenbio.com

DJ@drenbio.com

FL@drenbio.com

JD@drenbio.com

Frequently Asked Questions

What is Dren Bio's official website and social media links?

Dren Bio's official website is drenbio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Dren Bio generate?

As of October 2026, Dren Bio's annual revenue is estimated to be $50M - $100M.

What is Dren Bio's SIC code and NAICS code?

Dren Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Dren Bio have currently?

As of October 2026, Dren Bio has approximately 99 employees across 3 continents, including North America, Europe and Africa. Key team members include Senior Vice President, Regulatory Affairs: S. G., Senior Vice President, Head Of Oncology Clinical Development: W. H. and Senior Director Business Development: B. T. Explore Dren Bio's employee directory with LeadIQ.

What industry does Dren Bio belong to?

Dren Bio operates in the Biotechnology Research industry.

What technology does Dren Bio use?

Dren Bio's tech stack includes CookieYes, Microsoft Excel, Microsoft 365, Veeva Systems, Microsoft Office, Smartsheet, Box and Adobe Creative Suite.

What is Dren Bio's email format?

Dren Bio's email format typically follows the pattern of FLast@drenbio.com. Find more Dren Bio email formats with LeadIQ.

How much funding has Dren Bio raised to date?

As of October 2026, Dren Bio has raised $155M in funding. The last funding round occurred on Jul 24, 2024 for $25M.

Dren Bio

Q: What is Dren Bio's official website and social media links?

Dren Bio's official website is drenbio.com. Dren Bio has social profiles on LinkedIn.

Q: How many employees does Dren Bio have currently?

Dren Bio has approximately 99 employees.

Q: What technology does Dren Bio use?

Dren Bio's tech stack includes jQuery Migrate, Apache HTTP Server, Google Analytics, Microsoft Excel, Microsoft Word.

Q: What is Dren Bio's NAICS code?

Dren Bio's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchCalifornia, United States51-200 Employees

Dren Bio is a biotechnology company based in San Carlos, California, focused on developing protein-based technologies to deplete pathogenic cells and agents across multiple diseases. It operates within the biotechnology research sector, pursuing therapeutics that leverage protein-based mechanisms to address disease drivers. As a mid-sized organization, it maintains a focused R&D footprint and collaborates with larger partners to advance its programs.

The company has pursued strategic collaborations with major pharmaceutical developers, including partnerships with Novartis and Sanofi to advance cancer and autoimmune disease programs. These partnerships illustrate Dren Bio's position in the industry as a collaborator for larger companies seeking innovative protein-based approaches.

Insights

Similar companies to Dren Bio

Dren Bio Tech Stack

Media & News

On Dec 15th '25, Dren Bio, Inc. enters a strategic collaboration with Sanofi to develop therapies for autoimmune diseases, receiving $100 million upfront and eligibility for up to $1.7 billion in milestone payments.

Dren Bio, Inc. receives the prestigious 2025 Prix Galien USA Award for Best biotech Startup from the Galien Foundation in 2025.

Dren Bio, Inc. sells Sanofi a bispecific antibody being tested in non-Hodgkin lymphoma for $600M upfront and up to $1.9 billion in total payments.

Dren Bio, Inc. is developing DR-0201, a bispecific antibody targeting CD8-positive T cells that is currently in Phase 1 clinical trials for patients with B-cell non-Hodgkin lymphoma.

Dr. Will leaves Dren Bio, Inc. after serving as Chief Medical Officer to join Autolus.

In Jul '24, Dren Bio, Inc. and Novartis Pharma ink a $3 billion agreement to develop bispecific antibodies for cancer.

Dren Bio, Inc. is set to receive a $25M equity investment from Novartis as part of a $150 million upfront payment under a strategic collaboration announced on Jul 24th '24 to discover and develop bispecific antibodies for cancer indications.

Dren Bio's Email Address Formats